<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD003953.pub2" GROUP_ID="NEONATAL" ID="300402100311070704" MERGED_FROM="" MODIFIED="2012-05-15 01:30:46 +0100" MODIFIED_BY="Diane Haughton" NOTES="&lt;p&gt;Exported from Review Manager 4.2.1&lt;br&gt;Exported from Review Manager 4.2.2&lt;br&gt;Exported from Review Manager 4.2.1&lt;br&gt;do not remove&lt;/p&gt;&lt;p&gt;CL 1/03 (protocol)&lt;/p&gt;&lt;p&gt;CL 1/04 (review)&lt;/p&gt;&lt;p&gt;sent to Loni for update Dec 5/06&lt;/p&gt;" NOTES_MODIFIED="2012-05-14 11:02:46 -0400" NOTES_MODIFIED_BY="Diane Haughton" REVIEW_NO="" REVMAN_SUB_VERSION="5.1.6" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="4.0">
<COVER_SHEET MODIFIED="2012-05-15 01:30:46 +0100" MODIFIED_BY="Diane Haughton">
<TITLE MODIFIED="2012-03-28 05:02:47 -0400" MODIFIED_BY="[Empty name]">Antifungal therapy for newborn infants with invasive fungal infection</TITLE>
<CONTACT MODIFIED="2012-05-15 01:30:46 +0100" MODIFIED_BY="Diane Haughton"><PERSON ID="11151" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>William</FIRST_NAME><LAST_NAME>McGuire</LAST_NAME><POSITION>Professor of Child Health</POSITION><EMAIL_1>William.McGuire@hyms.ac.uk</EMAIL_1><ADDRESS><ORGANISATION>Hull York Medical School &amp; Centre for Reviews and Dissemination, University of York</ORGANISATION><CITY>York</CITY><REGION>Y010 5DD</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>44 01904 321695</PHONE_1><FAX_1>44 01904 321696</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2012-05-15 01:30:46 +0100" MODIFIED_BY="Diane Haughton"><PERSON ID="15188" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Linda</FIRST_NAME><LAST_NAME>Clerihew</LAST_NAME><SUFFIX>MRCPCH</SUFFIX><POSITION>Consultant Paediatrician</POSITION><EMAIL_1>linda.clerihew@nhs.net</EMAIL_1><ADDRESS><DEPARTMENT>Department of Paediatrics</DEPARTMENT><ORGANISATION>Tayside Children's Hospital</ORGANISATION><CITY>Dundee</CITY><ZIP>DD1 9SY</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 1382 632991</PHONE_1></ADDRESS></PERSON><PERSON ID="11151" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>William</FIRST_NAME><LAST_NAME>McGuire</LAST_NAME><POSITION>Professor of Child Health</POSITION><EMAIL_1>William.McGuire@hyms.ac.uk</EMAIL_1><ADDRESS><ORGANISATION>Hull York Medical School &amp; Centre for Reviews and Dissemination, University of York</ORGANISATION><CITY>York</CITY><REGION>Y010 5DD</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>44 01904 321695</PHONE_1><FAX_1>44 01904 321696</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2012-04-17 15:20:14 -0400" MODIFIED_BY="Diane Haughton">
<UP_TO_DATE>
<DATE DAY="3" MONTH="4" YEAR="2012"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="2" MONTH="4" YEAR="2012"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="3" MONTH="4" YEAR="2014"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2003"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2004"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2004"/>
</DATES>
<WHATS_NEW MODIFIED="2012-04-17 15:45:20 -0400" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2012-04-17 15:25:35 -0400" MODIFIED_BY="[Empty name]">
<DATE DAY="17" MONTH="4" YEAR="2012"/>
<DESCRIPTION>
<P>The search was revised and updated in April 2012. Expanded population to all newborn infants (previously preterm infants).</P>
<P>No new trials for inclusion were identified.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2012-04-17 15:45:20 -0400" MODIFIED_BY="[Empty name]">
<DATE DAY="3" MONTH="4" YEAR="2012"/>
<DESCRIPTION>
<P>This updates the review "Antifungal therapy for newborn infants with invasive fungal infection" (<LINK REF="REF-Clerihew-2004" TYPE="REFERENCE">Clerihew 2004</LINK>).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2008-10-22 14:12:37 -0400" MODIFIED_BY="[Empty name]"/>
<SOURCES_OF_SUPPORT MODIFIED="2012-05-12 21:18:47 -0400" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2012-04-03 09:30:37 -0400" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2012-04-02 09:29:34 -0400" MODIFIED_BY="[Empty name]">
<NAME>NIHR Centre for Reviews and Dissemination</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2012-04-03 09:30:37 -0400" MODIFIED_BY="[Empty name]">
<NAME>Tayside Children's Hospital, Dundee</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2012-05-12 21:18:47 -0400" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2012-05-12 21:18:47 -0400" MODIFIED_BY="[Empty name]">
<NAME>Eunice Kennedy Shriver National Institute of Child Health and Human Development National Institutes of Health, Department of Health and Human Services</NAME>
<COUNTRY CODE="US">USA</COUNTRY>
<DESCRIPTION>
<P>Editorial support of the Cochrane Neonatal Review Group has been funded with Federal funds from the Eunice Kennedy Shriver National Institute of Child Health and Human Development National Institutes of Health, Department of Health and Human Services, USA, under Contract No. HHSN275201100016C.</P>
<P> </P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2012-05-12 21:20:58 -0400" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2012-05-12 21:20:58 -0400" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-10-22 14:14:16 -0400" MODIFIED_BY="[Empty name]">Systemic antifungal drugs for invasive fungal infection in preterm infants</TITLE>
<SUMMARY_BODY MODIFIED="2012-05-12 21:20:58 -0400" MODIFIED_BY="[Empty name]">
<P>Preterm and sick newborn infants are at risk of serious infections of the blood, brain and kidneys due to fungi such as Candida (the organism that causes thrush). Severe fungal infections are associated with high death rates and with long-term brain damage in newborn infants. A variety of different types of drugs for treating fungal infections are available. However, this systematic review found only very limited evidence (one small trial) to support the use of one type of antifungal drug over another. Until this uncertainty is resolved with new large trials, clinicians may continue to base their choice of antifungal agent on data extrapolated from studies in older children and adults.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2012-05-12 21:13:11 -0400" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2012-04-03 08:52:52 -0400" MODIFIED_BY="[Empty name]">
<P>A variety of antifungal drugs, drug preparations and drug combinations are available to treat newborn infants with suspected or confirmed invasive fungal infection. There is a need to assess their relative merits.<BR/>
</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2012-04-03 08:53:20 -0400" MODIFIED_BY="[Empty name]">
<P>To assess the effect of treatment with different antifungal drugs, drug preparations or drug combinations on mortality and morbidity in newborn infants with suspected or confirmed invasive fungal infection.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2012-05-12 21:13:11 -0400" MODIFIED_BY="[Empty name]">
<P>We used the standard search strategy of the Cochrane Neonatal Review Group. This included searches of the Cochrane Central Register of Controlled Trials (<I>The Cochrane Library</I>, 2012, Issue 2), MEDLINE, EMBASE, CINAHL (to March 2012), conference proceedings and previous reviews.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2012-03-28 09:54:51 -0400" MODIFIED_BY="[Empty name]">
<P>Randomised and quasi-randomised control trials comparing one antifungal agent or combination of agents with another in newborn infants with suspected or confirmed invasive fungal infection.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2012-05-12 21:13:11 -0400" MODIFIED_BY="[Empty name]">
<P>We extracted the data using the standard methods of the Cochrane Neonatal Review Group, with separate evaluation of trial quality and data extraction by each author, and synthesis of data using risk ratio and risk difference.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2012-05-12 21:13:11 -0400" MODIFIED_BY="[Empty name]">
<P>We identified only one small trial in which 24 newborn infants participated. This trial compared the use of fluconazole versus amphotericin B (plus 5-fluorocytosine if fungal meningitis present). The trial did not detect a statistically significant effect on mortality (risk ratio 0.73; 95% confidence interval 0.26 to 2.05).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2012-04-03 08:55:24 -0400" MODIFIED_BY="[Empty name]">
<P>There are insufficient data to inform practice. Large randomised controlled trials are required to compare antifungal drugs, drug preparations or drug combinations for treating newborn infants with invasive fungal infection.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2012-05-12 21:20:58 -0400" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2012-05-12 21:20:58 -0400" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2012-05-12 21:13:33 -0400" MODIFIED_BY="[Empty name]">
<P>Invasive fungal infection, predominantly due to Candida species, is an increasingly common cause of mortality and morbidity in preterm and sick newborn infants (<LINK REF="REF-Robinson-2009" TYPE="REFERENCE">Robinson 2009</LINK>). The increase in incidence over the past 25 years may be due to the increased survival rates for preterm and sick infants and the invasive and intensive nature of the care that these infants receive. Invasive fungal infection accounts for about 10% of all cases of late-onset invasive infection (diagnosed &gt; 72 hours after birth) in newborn infants. Preterm birth and low birth weight are the most important independent risk factors. The estimated incidence is 2% to 5% in very preterm or very low birth weight (VLBW) infants (<LINK REF="REF-Clerihew-2006" TYPE="REFERENCE">Clerihew 2006</LINK>; <LINK REF="REF-Vergnano-2011" TYPE="REFERENCE">Vergnano 2011</LINK>). In extremely preterm or extremely low birth weight infants, the incidence has been estimated to be as high as 10% (<LINK REF="REF-Karlowicz-2002" TYPE="REFERENCE">Karlowicz 2002</LINK>). Other specific risk factors for invasive fungal infection include fungal colonisation, severe illness at birth, the use of multiple courses of antibiotics, the use of parenteral nutrition, the presence of a central venous catheter and the use of histamine receptor subtype 2 antagonists (<LINK REF="REF-Saiman-2000" TYPE="REFERENCE">Saiman 2000</LINK>; <LINK REF="REF-Benjamin-2006" TYPE="REFERENCE">Benjamin 2006</LINK>; <LINK REF="REF-Blyth-2009" TYPE="REFERENCE">Blyth 2009</LINK>).</P>
<P>In addition to fungaemia, infants may develop fungal pneumonia, meningitis, renal tract infection, ophthalmitis, osteomyelitis, endocarditis, liver abscesses and skin abscesses (<LINK REF="REF-Benjamin-2003" TYPE="REFERENCE">Benjamin 2003</LINK>; <LINK REF="REF-Clerihew-2006" TYPE="REFERENCE">Clerihew 2006</LINK>). The estimated attributable mortality of invasive fungal infection in newborn infants is about 25%, higher than that associated with invasive bacterial infection (<LINK REF="REF-Stoll-1996" TYPE="REFERENCE">Stoll 1996</LINK>; <LINK REF="REF-Saiman-2000" TYPE="REFERENCE">Saiman 2000</LINK>; <LINK REF="REF-Makhoul-2002" TYPE="REFERENCE">Makhoul 2002</LINK>; <LINK REF="REF-Stoll-2002" TYPE="REFERENCE">Stoll 2002</LINK>; <LINK REF="REF-Benjamin-2003" TYPE="REFERENCE">Benjamin 2003</LINK>; <LINK REF="REF-Blyth-2009" TYPE="REFERENCE">Blyth 2009</LINK>). Invasive fungal infection is also associated with short- and long-term morbidity. In particular, fungal infection of the central nervous system has a significant impact on long-term neurodevelopmental outcome (<LINK REF="REF-Friedman-2000" TYPE="REFERENCE">Friedman 2000</LINK>; <LINK REF="REF-Benjamin-2003" TYPE="REFERENCE">Benjamin 2003</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2012-05-12 21:20:58 -0400" MODIFIED_BY="[Empty name]">
<P>Three classes of antifungal drugs are commonly available for treating newborn infants with invasive fungal infection (<LINK REF="REF-Frattarelli-2004" TYPE="REFERENCE">Frattarelli 2004</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="3">Polyenes</HEADING>
<P>The most commonly used drug is amphotericin B, a polyene antifungal agent that reacts with sterols in cell membranes to cause cell lysis. Amphotericin B is poorly absorbed via the enteral route and is given as an intravenous preparation. Drug toxicity, particularly nephrotoxicity, is a potential problem as amphotericin B also damages mammalian cell membranes. These adverse effects limit the total dose that may be given. The newer lipid complex formulations of amphotericin B deliver the active drug directly to the site of action on the fungal cell membrane. Because the lipid complex is more stable in mammalian cells, toxicity is reduced. Consequently, amphotericin B lipid complex can be given at higher total doses. There is good evidence of reduced nephrotoxicity with the lipid complex formulations compared with conventional amphotericin B in some groups of immunosuppressed children and adults (<LINK REF="REF-Johansen-2002a" TYPE="REFERENCE">Johansen 2002a</LINK>; <LINK REF="REF-Blyth-2010" TYPE="REFERENCE">Blyth 2010</LINK>). There are also some observational data to suggest lower toxicity in preterm infants (<LINK REF="REF-Weitkamp-1998" TYPE="REFERENCE">Weitkamp 1998</LINK>; <LINK REF="REF-Juster_x002d_Reicher-2000" TYPE="REFERENCE">Juster-Reicher 2000</LINK>; <LINK REF="REF-Adler_x002d_Shohet-2001" TYPE="REFERENCE">Adler-Shohet 2001</LINK>). However, the lipid complex formulations are very much more expensive than conventional amphotericin B. In current neonatal practice use is often restricted to infants who are intolerant of, or do not respond to, conventional amphotericin B.</P>
<P>Amphotericin B is highly protein bound and does not achieve good penetration into extracellular fluid spaces, including cerebrospinal fluid. Another drug is often used instead of, or in addition to, amphotericin B to treat preterm infants with suspected or confirmed fungal meningitis. The most commonly used additional agent is 5-fluorocytosine (flucytosine), a fluorinated pyrimidine anti-metabolite that competitively inhibits nucleic acid synthesis. 5-Fluorocytosine achieves very good penetration into the cerebrospinal fluid (<LINK REF="REF-Hill-1974" TYPE="REFERENCE">Hill 1974</LINK>). Since monotherapy is thought to increase the risk of the development of stable antifungal resistance, 5-fluorocytosine is usually prescribed with amphotericin B or another antifungal agent. Amphotericin B and 5-fluorocytosine are not antagonistic but the evidence for synergism is inconsistent and depends on the laboratory assessment method used (<LINK REF="REF-Keele-2001" TYPE="REFERENCE">Keele 2001</LINK>; <LINK REF="REF-Te-Dorsthorst-2002" TYPE="REFERENCE">Te Dorsthorst 2002</LINK>). 5-Fluorocytosine is very well absorbed via the enteral route. Oral and intravenous preparations are available. The known side effects of 5-fluorocytosine include hepatic toxicity and transient neutropenia. Bone marrow suppression has also been reported (<LINK REF="REF-Vermes-2000" TYPE="REFERENCE">Vermes 2000</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Azoles</HEADING>
<P>The second major class of antifungal agents available for treating preterm infants with invasive fungal infection is the azole group. These include triazoles (fluconazole, voriconazole) and imidazoles (miconazole, ketoconazole). These drugs bind preferentially to the fungal cytochromes P450 and interfere with ergosterol synthesis in the cell membrane. Azoles are well absorbed after enteral administration. A prolonged treatment course can therefore be given without the presence of an intravenous catheter. Some randomised controlled trials in immunosuppressed adults have reported that azole drugs are less toxic than conventional amphotericin B (<LINK REF="REF-Kontoyiannis-2001" TYPE="REFERENCE">Kontoyiannis 2001</LINK>). However, Cochrane systematic reviews urge caution in interpreting and applying this evidence as the findings of several trials in this population are likely to have been biased by methodological and analysis flaws (<LINK REF="REF-Johansen-2002b" TYPE="REFERENCE">Johansen 2002b;</LINK> <LINK REF="REF-Jorgensen-2006" TYPE="REFERENCE">Jorgensen 2006</LINK>).</P>
<P>There is little published experience of the use of imidazole drugs to treat invasive fungal infection in newborn infants (<LINK REF="REF-Tuck-1980" TYPE="REFERENCE">Tuck 1980</LINK>; <LINK REF="REF-McDougall-1982" TYPE="REFERENCE">McDougall 1982</LINK>). Triazoles, particularly fluconazole, are used more commonly in neonatal practice and appear to be a safe treatment for newborn infants. The most frequently reported side effect is transient elevation of plasma levels of creatinine or hepatic enzymes described in about 5% of infants treated with fluconazole (<LINK REF="REF-Huttova-1998" TYPE="REFERENCE">Huttova 1998</LINK>). There are also rare important side effects such as Stevens-Johnson syndrome reported in other populations of patients (<LINK REF="REF-Gussenhoven-1991" TYPE="REFERENCE">Gussenhoven 1991</LINK>). Additionally, there is a potential risk of adverse effects as a result of drug interactions with medications that are prescribed for newborn infants, including cisapride, theophylline and thiazide diuretics (<LINK REF="REF-Neely-2001" TYPE="REFERENCE">Neely 2001</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Echinocandins</HEADING>
<P>Echinocandins (caspofungin, micafungin and anidulafungin) are newer antifungal agents that act by inhibiting 1,3-&#946;-D-glucan synthase, a fungal enzyme necessary for cell wall synthesis (<LINK REF="REF-Sucher-2009" TYPE="REFERENCE">Sucher 2009</LINK>; <LINK REF="REF-Chen-2011" TYPE="REFERENCE">Chen 2011</LINK>). Caspofungin and micafungin have been reported to be as effective as amphotericin B but with fewer adverse effects and drug interactions in treating adults with suspected or confirmed invasive fungal infection (<LINK REF="REF-Falagas-2007" TYPE="REFERENCE">Falagas 2007</LINK>; <LINK REF="REF-Kuse-2007" TYPE="REFERENCE">Kuse 2007</LINK>). However, there are few pharmacokinetic, safety or efficacy data relevant to children or infants (<LINK REF="REF-Heresi-2006a" TYPE="REFERENCE">Heresi 2006a</LINK>; <LINK REF="REF-Blyth-2010" TYPE="REFERENCE">Blyth 2010</LINK>; <LINK REF="REF-VandenBussche-2010" TYPE="REFERENCE">VandenBussche 2010</LINK>; <LINK REF="REF-Caudle-2012" TYPE="REFERENCE">Caudle 2012</LINK>). The published experience in newborn infants consists mainly of case reports of treatment of fungal infections unresponsive or resistant to amphotericin B and fluconazole (<LINK REF="REF-Odio-2004" TYPE="REFERENCE">Odio 2004</LINK>; <LINK REF="REF-Natarajan-2005" TYPE="REFERENCE">Natarajan 2005</LINK>; <LINK REF="REF-Manzar-2006" TYPE="REFERENCE">Manzar 2006</LINK>; <LINK REF="REF-Yalaz-2006" TYPE="REFERENCE">Yalaz 2006</LINK>; <LINK REF="REF-Smith-2007" TYPE="REFERENCE">Smith 2007</LINK>). Echinocandin resistance after prolonged use selects fungi with a mutation in the 1,3-&#946;-D-glucan synthase gene has been described (<LINK REF="REF-Krogh_x002d_Madsen-2006" TYPE="REFERENCE">Krogh-Madsen 2006</LINK>; <LINK REF="REF-Laverdiere-2006" TYPE="REFERENCE">Laverdiere 2006</LINK>; <LINK REF="REF-Baixench-2007" TYPE="REFERENCE">Baixench 2007</LINK>). Reported side effects are generally mild and transient but acute hepatitis has been associated with micafungin use (<LINK REF="REF-King-2009" TYPE="REFERENCE">King 2009</LINK>).</P>
</SUBSECTION>
</INTERVENTION>
<IMPORTANCE MODIFIED="2012-04-02 09:43:06 -0400" MODIFIED_BY="[Empty name]">
<P>Given the important differences in the epidemiology and pathogenesis of invasive fungal infection in newborn infants compared with older children and adults, and the potential for the choice of antifungal drug or drug preparation or combination to affect outcomes for newborn infants with invasive fungal infection, we reviewed the available evidence to determine if there are any implications for current practice or for future research (<LINK REF="REF-Blyth-2009" TYPE="REFERENCE">Blyth 2009</LINK>).</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2012-03-28 10:28:20 -0400" MODIFIED_BY="[Empty name]">
<P>To assess the effect of treatment with one antifungal drug or drug combination or preparation versus another on mortality and morbidity in newborn infants with invasive fungal infection.</P>
</OBJECTIVES>
<METHODS MODIFIED="2012-05-12 21:20:58 -0400" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2012-05-12 21:20:58 -0400" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2012-05-12 21:20:58 -0400" MODIFIED_BY="[Empty name]">
<OL>
<LI>Controlled trials utilising either random or quasi-random patient allocation.</LI>
<LI>Cluster randomised trials, where the unit of randomisation is the neonatal nursery/unit/centre.</LI>
</OL>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2012-05-12 21:14:16 -0400" MODIFIED_BY="[Empty name]">
<P>Newborn infants with confirmed or suspected invasive fungal infection. We defined "confirmed" invasive fungal infection as:</P>
<UL>
<LI>culture of fungus from a sterile site, such as cerebrospinal fluid, blood, urine, bone or joint, peritoneum, pleural space. Blood cultures should have been obtained from peripheral sites, not from indwelling catheters. Urine samples should have been obtained from sterile urethral catheterisation or suprapubic aspiration of the bladder, not from indwelling catheters or from urine 'bag' samples (since organisms isolated from these may represent perineal contamination);</LI>
<LI>findings on ophthalmological examination consistent with fungal ophthalmitis or retinitis;</LI>
<LI>pathognomonic findings on renal ultrasound examination: 'renal fungal balls'.</LI>
</UL>
<P>We defined 'suspected' invasive fungal infection pragmatically as an individual clinician's choice to prescribe a systemic antifungal agent based on the clinical suspicion of invasive fungal infection, but in the absence of a confirmed diagnosis as described above.</P>
<P>We did not include trials of antifungal prophylaxis or trials where antifungal therapy was given to treat superficial mucosal or skin infection.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2012-05-12 21:14:24 -0400" MODIFIED_BY="[Empty name]">
<P>One antifungal drug, drug combination or preparation versus another.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2012-04-17 15:37:57 -0400" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2012-04-17 15:37:43 -0400" MODIFIED_BY="[Empty name]">
<OL>
<LI>Death (all cause) prior to hospital discharge.</LI>
<LI>Neurodevelopmental outcomes assessed beyond infancy (neurological evaluations, developmental scores, and classifications of disability, including auditory and visual disability, non-ambulant cerebral palsy, developmental delay) and cognitive and educational outcomes (intelligence quotient and/or indices of educational achievement measured using a validated tool including school examination results).</LI>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2012-04-17 15:37:57 -0400" MODIFIED_BY="[Empty name]">
<OL>
<LI>Adverse reactions attributed to the antifungal agent that resulted in discontinuation of the therapy: abnormal hepatic function; abnormal renal function; gastrointestinal disturbance such as diarrhoea, feeding intolerance, or necrotising enterocolitis that results in cessation of enteral feeding; hypokalaemia; cardiac dysrhythmias; thrombophlebitis; rash (including Stevens-Johnson reactions); seizures.</LI>
<LI>Emergence of organisms resistant to antifungal agents as detected in infants enrolled in the study or, in cluster-randomised studies, on surveillance of other infants in the same unit in the study centre (including infants who are admitted to the unit following completion of the study).</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2012-05-12 21:14:48 -0400" MODIFIED_BY="[Empty name]">
<P>We used the standard search strategy of the Cochrane Neonatal Review Group.</P>
<ELECTRONIC_SEARCHES MODIFIED="2012-05-12 21:14:38 -0400" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Central Register of Controlled Trials (CENTRAL, <I>The Cochrane Library</I>, Issue 2, 2012), MEDLINE (1966 to March 2012), EMBASE (1980 to March 2012), and CINAHL (1982 to March 2012) using a combination of the following text words and MeSH terms: [Infant, Newborn OR Infant, Premature OR Infant, Low Birth Weight OR LBW OR infan* OR neonat*] AND [Mycoses/ OR fung* OR candid* OR Candida albicans OR Antifungal Agents/ OR Triazoles/ OR azole OR fluconazole OR diflucan OR miconazole OR ketoconazole OR voriconazole OR ravuconazole OR posaconazole OR amphotericin B OR amphotericin B OR ABLC OR Ambisome OR Abelcet OR Amphocil OR 5-fluorocytosine OR 5FC OR flucytosine OR echinocandin OR caspofungin OR micafungin OR anidulafungin]. The search outputs were limited with the relevant search filters for clinical trials as recommended in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We did not apply any language restriction.</P>
<P>We searched <A HREF="http://clinicaltrials.gov/">ClinicalTrials.gov</A> and <A HREF="http://www.controlled-trials.com/">Current Controlled Trials</A> for completed or ongoing trials.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2012-05-12 21:14:48 -0400" MODIFIED_BY="[Empty name]">
<P>We examined the references in studies identified as potentially relevant. We also searched the abstracts from the annual meetings of the Pediatric Academic Societies (1993 to 2011), the European Society for Paediatric Research (1995 to 2011), the UK Royal College of Paediatrics and Child Health (2000 to 2011) and the Perinatal Society of Australia and New Zealand (2000 to 2012). We considered trials reported only as abstracts to be eligible if sufficient information was available from the report, or from contact with the authors, to fulfil the inclusion criteria.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2012-05-12 21:16:01 -0400" MODIFIED_BY="[Empty name]">
<P>We used the standard methods of the Cochrane Neonatal Review Group.</P>
<STUDY_SELECTION MODIFIED="2012-05-12 21:14:57 -0400" MODIFIED_BY="[Empty name]">
<P>The two review authors screened the title and abstract of all studies identified by the above search strategy. We reassessed the full text of any potentially eligible reports and excluded those studies that did not meet all of the inclusion criteria. We discussed any disagreements until consensus was achieved.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2012-05-12 21:15:21 -0400" MODIFIED_BY="[Empty name]">
<P>We used a data collection form to aid extraction of relevant information from each included study. The two review authors extracted the data separately. We discussed any disagreements until consensus was achieved. We asked the investigators for further information if data from the trial reports were insufficient.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2012-05-12 21:15:21 -0400" MODIFIED_BY="[Empty name]">
<P>We used the criteria and standard methods of the Cochrane Neonatal Review Group to assess the methodological quality of any included trials. Additional information from the trial authors was requested to clarify methodology and results as necessary. We evaluated and reported the following issues in the 'Risk of Bias' tables:</P>
<OL>
<LI>Sequence generation: w categorised the method used to generate the allocation sequence as:</LI>
<OL>
<LI>low risk: any random process (e.g. random number table; computer random number generator);</LI>
<LI>high risk: any non-random process (e.g. odd or even date of birth; patient case-record number);</LI>
<LI>unclear.</LI>
</OL>
<LI>Allocation concealment: we categorised the method used to conceal the allocation sequence as:</LI>
<OL>
<LI>low risk: (e.g. telephone or central randomisation; consecutively numbered sealed opaque envelopes);</LI>
<LI>high risk: open random allocation; unsealed or non-opaque envelopes, alternation; date of birth;</LI>
<LI>unclear.</LI>
</OL>
<LI>Blinding: we assessed blinding of participants, clinicians and carers, and outcome assessors separately for different outcomes and categorised the methods as:</LI>
<OL>
<LI>low risk;</LI>
<LI>high risk;</LI>
<LI>unclear.</LI>
</OL>
<LI>Incomplete outcome data: we described the completeness of data including attrition and exclusions from the analysis for each outcome and any reasons for attrition or exclusion where reported. We assessed whether missing data were balanced across groups or were related to outcomes. Where sufficient information was reported or supplied by the trial authors, we re-included missing data in the analyses. We categorised completeness as:</LI>
<OL>
<LI>low risk: &lt; 20% missing data;</LI>
<LI>high risk: <U>&gt;</U> 20% missing data;</LI>
<LI>unclear.</LI>
</OL>
</OL>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2012-05-12 21:15:21 -0400" MODIFIED_BY="[Empty name]">
<P>We calculated risk ratio (RR) and risk difference (RD) for dichotomous data and weighted mean difference (WMD) for continuous data, with respective 95% confidence intervals (CI). We determined the number needed to treat for benefit (NNTB) or harm (NNTH) for analyses with a statistically significant difference in the RD.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2012-03-28 10:05:42 -0400" MODIFIED_BY="[Empty name]">
<P>The unit of analysis is the participating infant in individually randomised trials and the neonatal unit for cluster randomised trials.</P>
</UNIT_OF_ANALYSIS>
<HETEROGENEITY_ASSESSMENT MODIFIED="2012-05-12 21:15:42 -0400" MODIFIED_BY="[Empty name]">
<P>We examined the treatment effects of individual trials and heterogeneity between trial results by inspecting the forest plots. We calculated the I<SUP>2</SUP> statistic for each RR analysis to quantify inconsistency across studies and describe the percentage of variability in effect estimates that may be due to heterogeneity rather than sampling error. If substantial heterogeneity (I<SUP>2</SUP> &gt; 50%) was detected, we explored the possible causes (e.g. differences in study design, participants, interventions or completeness of outcome assessments).</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2012-04-02 10:01:43 -0400" MODIFIED_BY="[Empty name]">
<P>If more than five trials were included in a meta-analysis, we planned to examine a funnel plot for asymmetry.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2012-05-12 21:16:01 -0400" MODIFIED_BY="[Empty name]">
<P>We used the fixed-effect model in RevMan 5.1 for meta-analysis (<LINK REF="REF-RevMan-2011" TYPE="REFERENCE">RevMan 2011</LINK>).</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2012-04-17 15:40:35 -0400" MODIFIED_BY="[Empty name]">
<P>We pre-specified a subgroup analysis of outcomes for very preterm (&lt; 32 weeks) or VLBW infants (&lt; 1500 g).</P>
</SUBGROUP_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2012-05-12 21:20:58 -0400" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2012-05-12 21:16:01 -0400" MODIFIED_BY="[Empty name]">
<P>We identified only one eligible trial (<LINK REF="STD-Driessen-1996" TYPE="STUDY">Driessen 1996</LINK>). The trial, undertaken during 1992 to 1993 in two tertiary neonatal centres in South Africa, assessed the effect of treatment with fluconazole versus conventional amphotericin B (plus 5-fluorocytosine if meningitis suspected) in 24 newborn infants (22 of whom were preterm) with confirmed bloodstream fungal infection. Mortality was reported but the trial did not assess any long-term outcomes after hospital discharge. Data on adverse reactions to treatment including gastrointestinal disturbance or thrombophlebitis were recorded throughout the study period.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2012-05-12 21:16:01 -0400" MODIFIED_BY="[Empty name]">
<P>Randomisation was computer generated independently for the two centres and via a sealed envelope system for individual case allocation. Both preterm infants and term infants were eligible for inclusion in the trial and these groups were not randomised separately. There were not any statistically significant differences between treatment groups in infant characteristics at trial entry. Follow-up was complete with the exception of one infant in the fluconazole group who was excluded post-randomisation by the investigators as the infant did not have confirmed invasive fungal infection. The carers and assessors were blinded to randomisation. However, due to differences in the drug preparations, the carers and investigators were likely to be aware which drug each infant received.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2012-05-12 21:20:58 -0400" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Primary outcomes</HEADING>
<P>1. Death prior to hospital discharge (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>): four of 12 infants in the fluconazole group died before discharge versus five of 11 in the amphotericin B group (RR 0.73; 95% CI 0.26 to 2.05; RD -0.12; 95% CI -0.52 to 0.28).</P>
<P>2. Neurodevelopmental outcomes not reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Secondary outcomes</HEADING>
<P>1. This trial reported rates of adverse reactions. However, none of these resulted in discontinuation of treatment.</P>
<P>a. Hepatic function: there was no statistically significant difference in the plasma levels of the liver enzymes gamma-glutamyl transpeptidase, aspartate aminotransferase and alanine aminotransferase between the fluconazole and amphotericin groups at the end of treatment.<BR/>b. Thrombophlebitis (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>): one infant in the fluconazole group and five infants in the amphotericin group had evidence of thrombophlebitis resulting in skin abscesses (but not in discontinuation of treatment) (RR 0.18; 95% CI 0.03 to 1.33; RD -0.37; 95% CI -0.70 to -0.04).<BR/>c. Gastrointestinal disturbance: one infant in the fluconazole group had severe vomiting. However, this infant also had a disorder of branch chain amino acid metabolism.</P>
<P>2. Emergence of antifungal resistance is not reported in this study.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Subgroup analysis</HEADING>
<P>We were unable to undertake subgroup analysis of very preterm or VLBW infants.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2012-05-12 21:20:58 -0400" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2012-05-12 21:20:58 -0400" MODIFIED_BY="[Empty name]">
<P>We identified only one eligible study (<LINK REF="STD-Driessen-1996" TYPE="STUDY">Driessen 1996</LINK>). This small trial compared fluconazole with conventional amphotericin B as treatment for newborn infants with confirmed invasive fungal infection. Although the study was of good methodological quality, the trial was too small (total of 24 infants) to allow meaningful conclusions to be drawn.</P>
<P>We did not find any studies that compared the use of conventional amphotericin B with liposomal amphotericin B preparations.</P>
<P>We did not find any trials that assessed the effect of treatment with other azoles or echinocandins.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2012-05-12 21:20:58 -0400" MODIFIED_BY="[Empty name]">
<P>Our pre-specified outcomes did not include any specific measure of convenience of drug administration or of the cost of the treatment course although these may be related to the incidences of side effects that result in discontinuation of therapy. In the included study, the incidence of thrombophlebitis was borderline statistically significantly lower in the group treated with fluconazole compared to amphotericin B, but this complication did not result in discontinuation of treatment. There were no other instances of adverse events resulting in discontinuation of therapy. The trial also found that there were no statistically significant differences in duration of treatment, days in hospital after enrolment to the study or duration of need for a central venous line. However, the mean duration of intravenous antifungal therapy was statistically significantly lower for the fluconazole group (which is well absorbed orally and was prescribed enterally for part of the treatment course) compared with amphotericin B.</P>
</APPLICABILITY_OF_FINDINGS>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2012-05-12 21:20:58 -0400" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2012-03-28 10:48:30 -0400" MODIFIED_BY="[Empty name]">
<P>There are insufficient data to determine whether treatment with different antifungal drugs or drug combinations affects mortality and adverse neurodevelopmental outcomes in newborn infants with suspected or confirmed invasive fungal infection. In the absence of these data, the choice of therapy may be affected by other considerations such as the cost of the treatment course and the convenience of use.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2012-05-12 21:20:58 -0400" MODIFIED_BY="[Empty name]">
<P>Very large pragmatic randomised controlled trials would be required to determine if any of the newer antifungal drugs or preparations reduce mortality and adverse neurodevelopmental outcomes compared with conventional amphotericin B. Trials should also address the effect of increased use of particular agents on the emergence of organisms resistant to antifungal drugs. This may necessitate the use of a cluster-randomised trial design, with the neonatal centre as the unit of randomisation. Further research may also determine the relative convenience and cost effectiveness of the available drugs. For example, drugs that are well absorbed orally may be more convenient and cost effective in practice.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2012-05-12 21:20:58 -0400" MODIFIED_BY="[Empty name]">
<P>We thank Dr M Dreissen, Dr S Wainer and Prof P Cooper for providing unpublished data from their study (<LINK REF="STD-Driessen-1996" TYPE="STUDY">Driessen 1996</LINK>).</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2012-04-03 11:11:27 -0400" MODIFIED_BY="[Empty name]">
<P>None.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2012-05-12 21:20:58 -0400" MODIFIED_BY="Anne Lawson">
<P>The first review author (LC) screened the title and abstract of all studies identified by the above search strategy. Both review authors re-screened the full text of the report of each study identified as of potential relevance. The review authors resolved any disagreements by discussion until consensus was achieved. Both review authors used a data collection form to aid extraction of relevant information and data from each included study. Each review author extracted the data separately, compared data and resolved differences by consensus. Both review authors contributed to the analysis and interpretation of the data, and the completion of the review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2012-04-03 11:15:41 -0400" MODIFIED_BY="[Empty name]">
<P>We have updated the <LINK TAG="BACKGROUND" TYPE="SECTION">Background</LINK> section and expanded and re-run the <LINK TAG="ELECTRONIC_SEARCHES" TYPE="SECTION">Electronic searches</LINK>. We have also expanded the <LINK TAG="CRIT_PARTICIPANTS" TYPE="SECTION">Types of participants</LINK> from preterm infants to all newborn infants (with appropriate <LINK TAG="SUBGROUP_ANALYSIS" TYPE="SECTION">Subgroup analysis and investigation of heterogeneity</LINK> specified).<BR/>
</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2012-05-12 21:20:58 -0400" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2012-05-12 21:20:58 -0400" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2012-05-12 21:20:58 -0400" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Driessen-1996" MODIFIED="2012-05-12 21:20:58 -0400" MODIFIED_BY="[Empty name]" NAME="Driessen 1996" YEAR="1996">
<REFERENCE MODIFIED="2012-05-12 21:20:58 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Driessen M, Ellis JB, Cooper PA, Wainer S, Muwazi F, Hahn D, et al</AU>
<TI>Fluconazole versus amphotericin B for the treatment of neonatal fungal septicemia: a prospective randomized trial</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>1996</YR>
<VL>15</VL>
<PG>1107-12</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8970221  8970221  8970221"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES/>
<AWAITING_STUDIES MODIFIED="2012-04-02 09:16:26 -0400" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES MODIFIED="2012-04-02 09:16:51 -0400" MODIFIED_BY="[Empty name]"/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2012-05-12 21:20:58 -0400" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2012-05-12 21:20:58 -0400" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Adler_x002d_Shohet-2001" MODIFIED="2008-10-22 14:16:13 -0400" MODIFIED_BY="[Empty name]" NAME="Adler-Shohet 2001" TYPE="JOURNAL_ARTICLE">
<AU>Adler-Shohet F, Waskin H, Lieberman JM</AU>
<TI>Amphotericin B lipid complex for neonatal invasive candidiasis</TI>
<SO>Archives of Disease in Childhood. Fetal and Neonatal Edition</SO>
<YR>2001</YR>
<VL>84</VL>
<PG>F131-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Baixench-2007" MODIFIED="2012-04-03 11:19:13 -0400" MODIFIED_BY="[Empty name]" NAME="Baixench 2007" TYPE="JOURNAL_ARTICLE">
<AU>Baixench MT, Aoun N, Desnos-Ollivier M, Garcia-Hermoso D, Bretagne S, Ramires S, et al</AU>
<TI>Acquired resistance to echinocandins in Candida albicans: case report and review</TI>
<SO>The Journal of Antimicrobial Chemotherapy</SO>
<YR>2007</YR>
<VL>59</VL>
<PG>1076-83</PG>
<IDENTIFIERS MODIFIED="2012-04-02 09:35:22 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="17468115"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Benjamin-2003" MODIFIED="2012-04-03 11:19:24 -0400" MODIFIED_BY="[Empty name]" NAME="Benjamin 2003" TYPE="JOURNAL_ARTICLE">
<AU>Benjamin DK Jr, Poole C, Steibach WJ, Rowen JL, Walsh TJ</AU>
<TI>Neonatal candidemia and end-organ damage: a critical appraisal of the literature using meta-analytic techniques</TI>
<SO>Pediatrics</SO>
<YR>2003</YR>
<VL>112</VL>
<PG>634-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Benjamin-2006" MODIFIED="2012-04-17 16:06:06 -0400" MODIFIED_BY="[Empty name]" NAME="Benjamin 2006" TYPE="JOURNAL_ARTICLE">
<AU>Benjamin DK Jr, Stoll BJ, Fanaroff AA, McDonald SA, Oh W, Higgins RD, et al</AU>
<TI>Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months</TI>
<SO>Pediatrics</SO>
<YR>2006</YR>
<VL>117</VL>
<PG>84-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Blyth-2009" MODIFIED="2012-03-30 04:26:37 -0400" MODIFIED_BY="[Empty name]" NAME="Blyth 2009" TYPE="JOURNAL_ARTICLE">
<AU>Blyth CC, Chen SC, Slavin MA, Serena C, Nguyen Q, Marriott D, et al</AU>
<TI>Not just little adults: candidemia epidemiology, molecular characterization, and antifungal susceptibility in neonatal and pediatric patients</TI>
<SO>Pediatrics</SO>
<YR>2009</YR>
<VL>123</VL>
<PG>1360-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Blyth-2010" MODIFIED="2012-04-17 16:09:39 -0400" MODIFIED_BY="[Empty name]" NAME="Blyth 2010" TYPE="COCHRANE_REVIEW">
<AU>Blyth CC, Hale K, Palasanthiran P, O'Brien T, Bennett MH</AU>
<TI>Antifungal therapy in infants and children with proven, probable or suspected invasive fungal infections</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2012-04-17 16:09:39 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-04-17 16:09:39 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006343.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Caudle-2012" MODIFIED="2012-04-17 16:12:15 -0400" MODIFIED_BY="[Empty name]" NAME="Caudle 2012" TYPE="JOURNAL_ARTICLE">
<AU>Caudle KE, Inger AG, Butler DR, Rogers PD</AU>
<TI>Echinocandin use in the neonatal intensive care unit</TI>
<SO>The Annals of Pharmacotherapy</SO>
<YR>2012</YR>
<VL>46</VL>
<PG>108-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chen-2011" MODIFIED="2012-04-03 11:21:08 -0400" MODIFIED_BY="[Empty name]" NAME="Chen 2011" TYPE="JOURNAL_ARTICLE">
<AU>Chen SC, Slavin MA, Sorrell TC</AU>
<TI>Echinocandin antifungal drugs in fungal infections: a comparison</TI>
<SO>Drugs</SO>
<YR>2011</YR>
<VL>71</VL>
<PG>11-41</PG>
<IDENTIFIERS MODIFIED="2012-04-02 07:30:38 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="21175238"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Clerihew-2006" MODIFIED="2012-04-17 16:14:09 -0400" MODIFIED_BY="[Empty name]" NAME="Clerihew 2006" TYPE="JOURNAL_ARTICLE">
<AU>Clerihew L, Lamagni TL, Brocklehurst P, McGuire W</AU>
<TI>Invasive fungal infection in very low birthweight infants: national prospective surveillance study</TI>
<SO>Archives of Disease in Childhood. Fetal and Neonatal Edition</SO>
<YR>2006</YR>
<VL>91</VL>
<PG>F188-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Falagas-2007" MODIFIED="2012-04-03 11:21:49 -0400" MODIFIED_BY="[Empty name]" NAME="Falagas 2007" TYPE="JOURNAL_ARTICLE">
<AU>Falagas ME, Ntziora F, Betsi GI, Samonis G</AU>
<TI>Caspofungin for the treatment of fungal infections: a systematic review of randomized controlled trials</TI>
<SO>International Journal of Antimicrobial Agents</SO>
<YR>2007</YR>
<VL>29</VL>
<PG>136-43</PG>
<IDENTIFIERS MODIFIED="2012-04-02 07:26:23 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="17207609"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Frattarelli-2004" MODIFIED="2012-04-02 05:30:02 -0400" MODIFIED_BY="[Empty name]" NAME="Frattarelli 2004" TYPE="JOURNAL_ARTICLE">
<AU>Frattarelli DA, Reed MD, Giacoia GP, Aranda JV</AU>
<TI>Antifungals in systemic neonatal candidiasis</TI>
<SO>Drugs</SO>
<YR>2004</YR>
<VL>64</VL>
<PG>949-68</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Friedman-2000" MODIFIED="2008-10-22 14:18:15 -0400" MODIFIED_BY="[Empty name]" NAME="Friedman 2000" TYPE="JOURNAL_ARTICLE">
<AU>Friedman S, Richardson SE, Jacobs SE, O'Brien K</AU>
<TI>Systemic candida infection in extremely low birth weight infants: short term morbidity and long term neurodevelopmental outcome</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2000</YR>
<VL>19</VL>
<PG>499-504</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gussenhoven-1991" MODIFIED="2012-05-12 21:20:58 -0400" MODIFIED_BY="Anne Lawson" NAME="Gussenhoven 1991" TYPE="JOURNAL_ARTICLE">
<AU>Gussenhoven MJ, Haak A, Peereboom-Wynia JD, van't Wout JW</AU>
<TI>Stevens-Johnson syndrome after fluconazole</TI>
<SO>Lancet</SO>
<YR>1991</YR>
<VL>338</VL>
<PG>120</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Heresi-2006a" MODIFIED="2012-04-03 11:30:35 -0400" MODIFIED_BY="[Empty name]" NAME="Heresi 2006a" TYPE="JOURNAL_ARTICLE">
<AU>Heresi GP, Gerstmann DR, Reed MD, van den Anker JN, Blumer JL, Kovanda L, et al</AU>
<TI>The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2006</YR>
<VL>25</VL>
<PG>1110-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2012-05-12 21:20:58 -0400" MODIFIED_BY="Anne Lawson" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hill-1974" NAME="Hill 1974" TYPE="JOURNAL_ARTICLE">
<AU>Hill HR, Mitchell TG, Matsen JM, Quie PG</AU>
<TI>Recovery from disseminated candidiasis in a premature neonate</TI>
<SO>Pediatrics</SO>
<YR>1974</YR>
<VL>53</VL>
<PG>748-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Huttova-1998" MODIFIED="2012-05-12 21:20:58 -0400" MODIFIED_BY="[Empty name]" NAME="Huttova 1998" TYPE="JOURNAL_ARTICLE">
<AU>Huttova M, Hartmanova I, Kralinsky K, Filka J, Uher J, Kurak J, et al</AU>
<TI>Candida fungemia in neonates treated with fluconazole: report of forty cases, including eight with meningitis</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>1998</YR>
<VL>17</VL>
<PG>1012-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Johansen-2002a" MODIFIED="2012-04-17 16:16:28 -0400" MODIFIED_BY="[Empty name]" NAME="Johansen 2002a" TYPE="COCHRANE_REVIEW">
<AU>Johansen HK, Gotzsche PC</AU>
<TI>Amphotericin B lipid soluble formulations vs amphotericin B in cancer patients with neutropenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2012-04-17 16:16:17 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-04-17 16:16:17 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000969"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Johansen-2002b" MODIFIED="2012-04-17 16:16:40 -0400" MODIFIED_BY="[Empty name]" NAME="Johansen 2002b" TYPE="COCHRANE_REVIEW">
<AU>Johansen HK, Gotzsche PC</AU>
<TI>Amphotericin B versus fluconazole for controlling fungal infections in neutropenic cancer patients</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>4</NO>
<CY>Oxford</CY>
<IDENTIFIERS MODIFIED="2012-04-17 16:16:37 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-04-17 16:16:37 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000239"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Jorgensen-2006" MODIFIED="2012-04-17 16:18:04 -0400" MODIFIED_BY="[Empty name]" NAME="Jorgensen 2006" TYPE="COCHRANE_REVIEW">
<AU>Jorgensen KJ, Gotzsche PC, Johansen HK</AU>
<TI>Voriconazole versus amphotericin B in cancer patients with neutropenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2012-04-17 16:18:04 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-04-17 16:18:04 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004707.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Juster_x002d_Reicher-2000" MODIFIED="2012-05-12 21:20:58 -0400" MODIFIED_BY="Anne Lawson" NAME="Juster-Reicher 2000" TYPE="JOURNAL_ARTICLE">
<AU>Juster-Reicher A, Leibovitz E, Linder N, Amitay M, Flidel-Rimon O, Even-Tov S, et al</AU>
<TI>Liposomal amphotericin B (AmBisome) in the treatment of neonatal candidiasis in very low birth weight infants</TI>
<SO>Infection</SO>
<YR>2000</YR>
<VL>28</VL>
<PG>223-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Karlowicz-2002" MODIFIED="2012-05-12 21:20:58 -0400" MODIFIED_BY="[Empty name]" NAME="Karlowicz 2002" TYPE="JOURNAL_ARTICLE">
<AU>Karlowicz MG, Rowen JL, Barnes-Eley ML, Burke BL, Lawson ML, Bendel CM, et al</AU>
<TI>The role of birth weight and gestational age in distinguishing extremely low birth weight infants at high risk of developing candidemia from infants at low risk: a multicenter study</TI>
<SO>Pediatric Research</SO>
<YR>2002</YR>
<VL>51</VL>
<PG>301A</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Keele-2001" MODIFIED="2008-10-22 14:26:09 -0400" MODIFIED_BY="[Empty name]" NAME="Keele 2001" TYPE="JOURNAL_ARTICLE">
<AU>Keele DJ, DeLallo VC, Lewis RE, Ernst EJ, Klepser ME</AU>
<TI>Evaluation of amphotericin B and flucytosine in combination against Candida albicans and Cryptococcus neoformans using time-kill methodology</TI>
<SO>Diagnostic Microbiology and Infectious Disease</SO>
<YR>2001</YR>
<VL>41</VL>
<PG>121-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-King-2009" MODIFIED="2012-04-17 16:18:22 -0400" MODIFIED_BY="[Empty name]" NAME="King 2009" TYPE="JOURNAL_ARTICLE">
<AU>King KY, Edwards MS, Word BM</AU>
<TI>Hepatitis associated with micafungin use in a preterm infant</TI>
<SO>Journal of Perinatology</SO>
<YR>2009</YR>
<VL>29</VL>
<PG>320-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kontoyiannis-2001" MODIFIED="2012-04-02 07:39:39 -0400" MODIFIED_BY="[Empty name]" NAME="Kontoyiannis 2001" TYPE="JOURNAL_ARTICLE">
<AU>Kontoyiannis DP, Bodey GP, Mantzoros CS</AU>
<TI>Fluconazole vs. amphotericin B for the management of candidaemia in adults: a meta-analysis</TI>
<SO>Mycoses</SO>
<YR>2001</YR>
<VL>44</VL>
<PG>125-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Krogh_x002d_Madsen-2006" MODIFIED="2012-04-03 11:24:15 -0400" MODIFIED_BY="[Empty name]" NAME="Krogh-Madsen 2006" TYPE="JOURNAL_ARTICLE">
<AU>Krogh-Madsen M, Arendrup MC, Heslet L, Knudsen JD</AU>
<TI>Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2006</YR>
<VL>42</VL>
<PG>938-44</PG>
<IDENTIFIERS MODIFIED="2012-04-02 07:58:30 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="16511756"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kuse-2007" MODIFIED="2012-04-03 11:24:26 -0400" MODIFIED_BY="[Empty name]" NAME="Kuse 2007" TYPE="JOURNAL_ARTICLE">
<AU>Kuse ER, Chetchotisakd P, da Cunha CA, Ruhnke M, Barrios C, Raghunadharao D, et al</AU>
<TI>Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial</TI>
<SO>Lancet</SO>
<YR>2007</YR>
<VL>369</VL>
<PG>1519-27</PG>
<IDENTIFIERS MODIFIED="2012-04-02 07:22:40 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="17482982"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Laverdiere-2006" MODIFIED="2012-04-03 11:24:46 -0400" MODIFIED_BY="[Empty name]" NAME="Laverdiere 2006" TYPE="JOURNAL_ARTICLE">
<AU>Laverdiere M, Lalonde RG, Baril JG, Sheppard DC, Park S, Perlin DS</AU>
<TI>Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis</TI>
<SO>The Journal of Antimicrobial Chemotherapy</SO>
<YR>2006</YR>
<VL>57</VL>
<PG>705-8</PG>
<IDENTIFIERS MODIFIED="2012-04-02 07:58:30 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="16464893"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Makhoul-2002" NAME="Makhoul 2002" TYPE="JOURNAL_ARTICLE">
<AU>Makhoul IR, Sujov P, Smolkin T, Lusky A, Reichman B</AU>
<TI>Epidemiological, clinical, and microbiological characteristics of late-onset sepsis among very low birth weight infants in Israel: a national survey</TI>
<SO>Pediatrics</SO>
<YR>2002</YR>
<VL>109</VL>
<PG>34-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Manzar-2006" MODIFIED="2012-04-03 11:25:14 -0400" MODIFIED_BY="[Empty name]" NAME="Manzar 2006" TYPE="OTHER">
<AU>Manzar S, Kamat M, Pyati S</AU>
<TI>Caspofungin for refractory candidemia in neonates</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2006</YR>
<VL>25</VL>
<PG>282-3</PG>
<IDENTIFIERS MODIFIED="2012-04-02 09:35:22 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="16511405"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-McDougall-1982" MODIFIED="2008-10-22 14:26:55 -0400" MODIFIED_BY="[Empty name]" NAME="McDougall 1982" TYPE="JOURNAL_ARTICLE">
<AU>McDougall PN, Fleming PJ, Speller DC, Daish P, Speidel BD</AU>
<TI>Neonatal systemic candidiasis: a failure to respond to intravenous miconazole in two neonates</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>1982</YR>
<VL>57</VL>
<PG>884-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Natarajan-2005" MODIFIED="2012-04-03 11:25:33 -0400" MODIFIED_BY="[Empty name]" NAME="Natarajan 2005" TYPE="JOURNAL_ARTICLE">
<AU>Natarajan G, Lulic-Botica M, Rongkavilit C, Pappas A, Bedard M</AU>
<TI>Experience with caspofungin in the treatment of persistent fungemia in neonates</TI>
<SO>Journal of Perinatology</SO>
<YR>2005</YR>
<VL>25</VL>
<PG>770-7</PG>
<IDENTIFIERS MODIFIED="2012-04-02 09:35:22 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="16222348"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Neely-2001" NAME="Neely 2001" TYPE="JOURNAL_ARTICLE">
<AU>Neely MN, Schreiber JR</AU>
<TI>Fluconazole prophylaxis in the very low birth weight infant: not ready for prime time</TI>
<SO>Pediatrics</SO>
<YR>2001</YR>
<VL>107</VL>
<PG>404-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Odio-2004" MODIFIED="2012-04-03 11:26:05 -0400" MODIFIED_BY="[Empty name]" NAME="Odio 2004" TYPE="JOURNAL_ARTICLE">
<AU>Odio CM, Araya R, Pinto LE, Castro CE, Vasquez S, Alfaro B, et al</AU>
<TI>Caspofungin therapy of neonates with invasive candidiasis</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2004</YR>
<VL>23</VL>
<PG>1093-7</PG>
<IDENTIFIERS MODIFIED="2012-04-02 09:35:22 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="15626944"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2011" MODIFIED="2012-05-12 21:20:58 -0400" MODIFIED_BY="Anne Lawson" NAME="RevMan 2011" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2011</YR>
<EN>5.1</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Robinson-2009" MODIFIED="2012-04-03 11:26:18 -0400" MODIFIED_BY="[Empty name]" NAME="Robinson 2009" TYPE="JOURNAL_ARTICLE">
<AU>Robinson JL, Davies HD, Barton M, O'Brien K, Simpson K, Asztalos E, et al</AU>
<TI>Characteristics and outcome of infants with candiduria in neonatal intensive care - a Paediatric Investigators Collaborative Network on Infections in Canada (PICNIC) study</TI>
<SO>BMC Infectious Diseases</SO>
<YR>2009</YR>
<VL>9</VL>
<PG>183</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="19930662"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Saiman-2000" MODIFIED="2012-05-12 21:20:58 -0400" MODIFIED_BY="[Empty name]" NAME="Saiman 2000" TYPE="JOURNAL_ARTICLE">
<AU>Saiman L, Ludington E, Pfaller M, Rangel-Frausto S, Wiblin RT, Dawson J, et al</AU>
<TI>Risk factors for candidemia in neonatal intensive care unit patients. The National Epidemiology of Mycosis Survey Study Group</TI>
<SO>Pediatric Infectious Diseases Journal</SO>
<YR>2000</YR>
<VL>19</VL>
<PG>319-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Smith-2007" MODIFIED="2012-04-03 11:26:44 -0400" MODIFIED_BY="[Empty name]" NAME="Smith 2007" TYPE="JOURNAL_ARTICLE">
<AU>Smith PB, Steinbach WJ, Cotten CM, Schell WA, Perfect JR, Walsh TJ, et al</AU>
<TI>Caspofungin for the treatment of azole resistant candidemia in a premature infant</TI>
<SO>Journal of Perinatology</SO>
<YR>2007</YR>
<VL>27</VL>
<PG>127-9</PG>
<IDENTIFIERS MODIFIED="2012-04-02 09:35:22 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="17262048"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Stoll-1996" MODIFIED="2012-05-12 21:20:58 -0400" MODIFIED_BY="[Empty name]" NAME="Stoll 1996" TYPE="JOURNAL_ARTICLE">
<AU>Stoll BJ, Gordon T, Korones SB, Shankaran S, Tyson JE, Bauer CR, et al</AU>
<TI>Late-onset sepsis in very low birth weight neonates: a report from the National Institute of Child Health and Human Development Neonatal Research Network</TI>
<SO>Journal of Pediatrics</SO>
<YR>1996</YR>
<VL>129</VL>
<PG>63-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stoll-2002" MODIFIED="2012-05-12 21:20:58 -0400" MODIFIED_BY="Anne Lawson" NAME="Stoll 2002" TYPE="JOURNAL_ARTICLE">
<AU>Stoll BJ, Hansen N, Fanaroff AA, Wright LL, Carlo WA, Ehrenkranz RA, et al</AU>
<TI>Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network</TI>
<SO>Pediatrics</SO>
<YR>2002</YR>
<VL>110</VL>
<PG>285-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sucher-2009" MODIFIED="2012-04-03 11:26:57 -0400" MODIFIED_BY="[Empty name]" NAME="Sucher 2009" TYPE="JOURNAL_ARTICLE">
<AU>Sucher AJ, Chahine EB, Balcer HE</AU>
<TI>Echinocandins: the newest class of antifungals</TI>
<SO>The Annals of Pharmacotherapy</SO>
<YR>2009</YR>
<VL>43</VL>
<PG>1647-57</PG>
<IDENTIFIERS MODIFIED="2012-04-02 07:35:17 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="19724014"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Te-Dorsthorst-2002" MODIFIED="2012-05-12 21:20:58 -0400" MODIFIED_BY="[Empty name]" NAME="Te Dorsthorst 2002" TYPE="JOURNAL_ARTICLE">
<AU>Te Dorsthorst DT, Verweij PE, Meletiadis J, Bergervoet M, Punt NC, Meis JF, et al</AU>
<TI>In vitro interaction of flucytosine combined with amphotericin B or fluconazole against thirty-five yeast isolates determined by both the fractional inhibitory concentration index and the response surface approach</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>2002</YR>
<VL>46</VL>
<PG>2982-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tuck-1980" MODIFIED="2012-05-12 21:20:58 -0400" MODIFIED_BY="[Empty name]" NAME="Tuck 1980" TYPE="JOURNAL_ARTICLE">
<AU>Tuck S</AU>
<TI>Neonatal systemic candidiasis treated with miconazole</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>1980</YR>
<VL>55</VL>
<PG>903-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-VandenBussche-2010" MODIFIED="2012-04-17 16:26:30 -0400" MODIFIED_BY="[Empty name]" NAME="VandenBussche 2010" TYPE="JOURNAL_ARTICLE">
<AU>VandenBussche HL, Van Loo DA</AU>
<TI>A clinical review of echinocandins in pediatric patients</TI>
<SO>The Annals of Pharmacotherapy</SO>
<YR>2010</YR>
<VL>44</VL>
<PG>166-77</PG>
<IDENTIFIERS MODIFIED="2012-04-02 07:38:12 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="20009006"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Vergnano-2011" MODIFIED="2012-04-03 11:27:43 -0400" MODIFIED_BY="[Empty name]" NAME="Vergnano 2011" TYPE="JOURNAL_ARTICLE">
<AU>Vergnano S, Menson E, Kennea N, Embleton N, Russell AB, Watts T, et al</AU>
<TI>Neonatal infections in England: the NeonIN surveillance network</TI>
<SO>Archives of Disease in Childhood Fetal and Neonatal Edition</SO>
<YR>2011</YR>
<VL>96</VL>
<PG>F9-F14</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="20876594"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Vermes-2000" NAME="Vermes 2000" TYPE="JOURNAL_ARTICLE">
<AU>Vermes A, van Der Sijs H, Guchelaar HJ</AU>
<TI>Flucytosine: correlation between toxicity and pharmacokinetic parameters</TI>
<SO>Chemotherapy</SO>
<YR>2000</YR>
<VL>46</VL>
<PG>86-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Weitkamp-1998" MODIFIED="2012-05-12 21:20:58 -0400" MODIFIED_BY="Anne Lawson" NAME="Weitkamp 1998" TYPE="JOURNAL_ARTICLE">
<AU>Weitkamp JH, Poets CF, Sievers R, Musswessels E, Groneck P, Thomas P, et al</AU>
<TI>Candida infection in very low birth-weight infants: outcome and nephrotoxicity of treatment with liposomal amphotericin B (AmBisome)</TI>
<SO>Infection</SO>
<YR>1998</YR>
<VL>26</VL>
<PG>11-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yalaz-2006" MODIFIED="2012-04-03 11:27:58 -0400" MODIFIED_BY="[Empty name]" NAME="Yalaz 2006" TYPE="OTHER">
<AU>Yalaz M, Akisu M, Hilmioglu S, Calkavur S, Cakmak B, Kultursay N</AU>
<TI>Successful caspofungin treatment of multidrug resistant Candida parapsilosis septicaemia in an extremely low birth weight neonate</TI>
<SO>Mycoses</SO>
<YR>2006</YR>
<VL>49</VL>
<PG>242-5</PG>
<IDENTIFIERS MODIFIED="2012-04-02 09:35:22 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="16681818"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2012-04-17 15:26:49 -0400" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Clerihew-2004" MODIFIED="2012-04-17 15:26:49 -0400" MODIFIED_BY="[Empty name]" NAME="Clerihew 2004" TYPE="COCHRANE_REVIEW">
<AU>Clerihew L, McGuire W</AU>
<TI>Systemic antifungal drugs for invasive fungal infection in preterm infants</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2012-04-17 15:26:49 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-04-17 15:26:49 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003953.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2012-04-17 16:11:42 -0400" MODIFIED_BY="[Empty name]"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2012-05-12 21:20:58 -0400" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2012-05-12 21:20:58 -0400" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2012-05-12 21:20:58 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Driessen-1996">
<CHAR_METHODS MODIFIED="2012-04-03 10:21:32 -0400" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-12 21:20:58 -0400" MODIFIED_BY="[Empty name]">
<P>24 newborn (22 preterm) infants with invasive fungal infection, aged less than 3 months old<BR/>June 1992 to June 1993 in 2 tertiary neonatal centres in Witwatersrand, South Africa</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-12 21:20:58 -0400" MODIFIED_BY="[Empty name]">
<P>Fluconazole 10 mg/kg intravenously or orally then 5 mg/kg once daily (n = 13), versus amphotericin B 1 mg/kg/day infused intravenously over 4 to 6 hours (n = 11)</P>
<P>Treatment continued until fungal cultures negative for 1 week and no laboratory evidence of infection</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-04-17 15:44:34 -0400" MODIFIED_BY="[Empty name]">
<P>Death before hospital discharge<BR/>Haematological, renal, hepatic functions; monitored weekly<BR/>Adverse reactions, convenience of use</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-12 21:20:58 -0400" MODIFIED_BY="[Empty name]">
<P>24 infants were recruited to the study but 1 infant in the fluconazole group was excluded post-randomisation by the investigators as the infant did not have confirmed invasive fungal infection</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2012-04-02 09:16:26 -0400" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2012-04-02 09:16:51 -0400" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2012-05-12 21:20:58 -0400" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2012-05-12 21:20:58 -0400" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-12 21:20:58 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Driessen-1996">
<DESCRIPTION>
<P>Computer-generated random sequence independently for the 2 centres and allocation using a sealed envelope system</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2012-05-12 21:20:58 -0400" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-05-12 21:20:58 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Driessen-1996">
<DESCRIPTION>
<P>Due to differences in the drug preparations, the carers and investigators were likely to be aware which drug each infant received</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2012-05-12 21:20:58 -0400" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-05-12 21:20:58 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Driessen-1996">
<DESCRIPTION>
<P>Due to differences in the drug preparations, the carers and investigators were likely to be aware which drug each infant received</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2012-05-12 21:20:58 -0400" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-05-12 21:20:58 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Driessen-1996">
<DESCRIPTION>
<P>Follow-up was complete with the exception of 1 infant in the fluconazole group who was excluded post-randomisation by the investigators as the infant did not have confirmed invasive fungal infection</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2012-05-12 21:20:58 -0400" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-12 21:20:58 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Driessen-1996">
<DESCRIPTION>
<P>Follow-up was complete with the exception of 1 infant in the fluconazole group who was excluded post-randomisation by the investigators as the infant did not have confirmed invasive fungal infection</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2012-05-12 21:20:58 -0400" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2012-05-12 21:20:58 -0400" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Fluconazole versus amphotericin B</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.052530873288899" CI_START="0.26200715651894807" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.31228969831190084" LOG_CI_START="-0.5816868461068132" LOG_EFFECT_SIZE="-0.13469857389745624" METHOD="MH" MODIFIED="2012-04-03 10:10:43 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.554768856599819" Q="0.0" RANDOM="NO" SCALE="5.062061452233393" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="11" WEIGHT="100.00000000000001" Z="0.5906292626046101">
<NAME>Mortality before hospital discharge</NAME>
<GROUP_LABEL_1>Fluconazole</GROUP_LABEL_1>
<GROUP_LABEL_2>Amphotericin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fluconazole</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours amphotericin</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.052530873288899" CI_START="0.26200715651894807" EFFECT_SIZE="0.7333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.31228969831190084" LOG_CI_START="-0.5816868461068132" LOG_EFFECT_SIZE="-0.13469857389745624" MODIFIED="2012-04-03 09:20:04 -0400" MODIFIED_BY="[Empty name]" ORDER="1142" O_E="0.0" SE="0.5251262474468171" STUDY_ID="STD-Driessen-1996" TOTAL_1="12" TOTAL_2="11" VAR="0.27575757575757576" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.3345526910851522" CI_START="0.02518530091440692" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.18333333333333332" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.12533572536652132" LOG_CI_START="-1.5988528558173587" LOG_EFFECT_SIZE="-0.7367585652254186" METHOD="MH" MODIFIED="2012-04-12 05:32:21 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.09393142861351507" Q="0.0" RANDOM="NO" SCALE="45.32227486227949" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="11" WEIGHT="100.00000000000001" Z="1.6750142866063027">
<NAME>Presence of thrombophlebitis</NAME>
<GROUP_LABEL_1>Fluconazole</GROUP_LABEL_1>
<GROUP_LABEL_2>Amphotericin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fluconazole</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours amphotericin</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3345526910851528" CI_START="0.02518530091440692" EFFECT_SIZE="0.18333333333333332" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.12533572536652154" LOG_CI_START="-1.5988528558173587" LOG_EFFECT_SIZE="-0.7367585652254186" MODIFIED="2012-04-12 05:32:21 -0400" MODIFIED_BY="[Empty name]" ORDER="1143" O_E="0.0" SE="1.0127969074585368" STUDY_ID="STD-Driessen-1996" TOTAL_1="12" TOTAL_2="11" VAR="1.0257575757575759" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2012-04-17 16:11:57 -0400" MODIFIED_BY="[Empty name]"/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>